Member Info for BOJO2020

Booyakasha! I like!!

Whilst the MM are more like cats; not in the slightest bit interested. But an excellent opportunity to top for me!

Yes thanks Burble for taking the time and answering so clearly as usual. Much appreciated.

Is it likely that oncology teams choose the drugs? So that in particular circumstances (backed by data) they do a trio including either checkpoint inhibitors. I guess what I am asking is can they work around the licences? I suppose anything is possible with data but Scancell licensing sounds very interesting.

I appreciate that I have put the horse before the cart. This will be all about data. The best options for patients may come over time as if SCIB1 proves useful I’d expect further studies. Let’s get efficacy first!

Sorry, just excited and keen to understand.

Let’s say that SCIB1 improves Mercks or BSM checkpoint inhibitors. One of them buys our platform. Would that prohibit one pharma from using it ( let’s say Merck). Or would BSM sell it to Merck under license?

You did say you didn’t mind silly questions!

Could be a great call Balerno1. I didn’t see the news flow coming in the way it has but did state the company would be busy behind the scenes so not to worry.

Redmile may ask, ‘where’s the other £9’ ;-)

Great timing WTP. I did the same last week and today

Redmile are majority share holders in RedX out if Manchester I believe. But yes Lindy looked good. Performed well and explained things in her usually gentle and understandable manner. She should be very proud. Hope her work has many miles to go!

Fair comment Ruck

I get the impression that liquid biopsy are seen as not quite being there by clinicians. Understandably so as each platform has its limitations. Apart from Parsortix. Angle have proven many times over that this is the real deal. They just have to get the right people to recognise this. The Solaris study and others will go a long way to ensuring Parsortix is used where it is needed, and in good time. Over to you Angle!

Still no interview? Is it just me or is that strange…

Placement, Sales, Partnership. This baby needs cash otherwise it stands still. Nothing wrong with funding but id not expect any serious institution to buy in the open market. They would much prefer to buy in an orderly manner.

I really do think that people need to toughen up about finances. Cash is the lifeblood of any GROWING business. Watching the pennies and standing still is not an option.

Anyway, with AN's track record and IG's acumen, expect this period of uncertainty to be put to bed in 3 to 6 months or so.

Very best of luck to our first patient and all those that follow

And a very reasonable share price. A good time to add? (rhetorical)

Chazzy

Present tense: we have 5 pharma customers for labs.

Also we are cash generative but AN does not expect profit in the near term. This is understandable in our scenario. I guess we will not be able to find out anytime soon about breakeven/profit as many moving targets and growth plans that are as yet not defined. I am sure AN & IG know better!

Sheerclass,

I thought the reason for the RENX price collapse was due to insurance issues; the democrats and republicans have not got their act together. Renx a bit of a dead duck without insurance implementation? I am not invested in that one but researched a long while back. Please correct me if I am wrong. I appreciate we would like to keep the subject about Angle.

ATB

Hi Early Bird,

I think its more complicated. After watching AN many times I believe he is looking too clinical trials and studies as route to market. Once Oncologist's have specif and convincing evidence from Parsortix, they would use it as part of their arsenal to defeat cancers. Evidence is key in their decision making and we have heard from many that, "we are not there yet.' . Right now the studies to date whilst very compelling and interesting appear not to give the vital thread they seek (because there are so many types of cancer and different circumstances). Its probably down to trial design and a need to prove Parsortix for FDA De Novo approval. Now that is done, Angle can start to be more specific (Solaris Study) and it becomes very interesting.

Re: buyouts. Hmm who knows. At some stage maybe. But a partnership is more likely IMO, that would give us the rocket fuel we need to quicken the pace in many regards. In the mean time, I expect Angle to work its way into the medical business just as mobile phones have. So a multi pronged approach and we can see that AN & IG have a successful entrepreneurial history.

Should say PDL-1

Xv,

Are you referring to the PD1 treatment? They have so many shots on goal and are often criticised for spinning too many plates. However I believe the science is in the right area. Burble, Bermuda Shorts and Inanco know their beans and I agree. Could be very successful.